Free tool
FAERS Monitor: Yartemlea
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761152 or its brand name (Yartemlea, Narsoplimab-Wuug). Reports on generic versions are filed under their own applications.
Reports
21
Serious
21
100% of reports
Hospitalization
8
Death reported
5
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- thrombotic microangiopathy5
- drug ineffective4
- thrombocytopenia3
- acute graft versus host disease in skin2
- acute kidney injury2
- cytopenia2
- disease recurrence2
- gastrointestinal haemorrhage2
- hypertension2
- hypervolaemia2
- respiratory failure2
- acute respiratory distress syndrome1
- acute respiratory failure1
- allogenic stem cell transplantation1
- anaemia vitamin b12 deficiency1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2021 | 3 |
| 2022 | 5 |
| 2023 | 4 |
| 2025 | 2 |
| 2026 | 7 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,138 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| allogenic stem cell transplantation | 1 | 6385.8 | 937.0 | 1,585 |
| anaemia vitamin b12 deficiency | 1 | 2029.5 | 299.1 | 505 |
| acute graft versus host disease in skin | 2 | 725.2 | 194.0 | 812 |
| thrombotic microangiopathySignal | 5 | 514.1 | 239.2 | 2,073 |
| hypervolaemia | 2 | 405.5 | 108.5 | 453 |
| cytopenia | 2 | 163.6 | 43.8 | 181 |
| acute respiratory distress syndrome | 1 | 56.6 | 8.4 | 13 |
| acute respiratory failure | 1 | 52.1 | 7.7 | 12 |
| disease recurrence | 2 | 42.1 | 11.3 | 45 |
| respiratory failure | 2 | 27.5 | 7.3 | 28 |
| thrombocytopeniaSignal | 3 | 26.9 | 9.4 | 51 |
| gastrointestinal haemorrhage | 2 | 24.0 | 6.4 | 24 |
| acute kidney injury | 2 | 13.1 | 3.5 | 12 |
| hypertension | 2 | 9.5 | 2.5 | 8 |
| drug ineffective | 4 | 3.0 | 1.3 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.